ICON will deploy Claude across 40,200 staff running clinical trials. Anthropic says enrolment, not science, delays up to 80% of them.
ICON deployed Claude in clinical trials targeting enrolment, the 80% bottleneck in trial delays. Anthropic prioritizes operational automation—logistics, protocol design—over discovery, proving frontier models drive measurable ROI in process work, not just research.
ICON plc has agreed a multi-year collaboration with Anthropic to put Claude across the clinical trial process.
The Dublin company is a contract research organisation, which means pharmaceutical firms pay it to run their trials. It employed roughly 40,200 people across 99 locations and 55 countries at the end of June.
Neither company disclosed financial terms.
What Anthropic just said about its own field
The interesting part is not the deal. It is the reasoning Anthropic gave for it.
Bristol Myers Squibb partners with Anthropic to deploy Claude AI across 30,000 employees, embedding agentic AI into drug…
Anthropic launched its AI for Science program offering free API credits for drug discovery research, followed by Claude for Life…
On Tuesday, Anthropic announced Claude Science, a new product that company leaders describe as an AI workbench for scientific…
The biopharma company will use the AI model across research, drug development, manufacturing, and commercial and medical affairs
The launch is part of Anthropic's life sciences and healthcare initiative, which the IPO-bound company has been developing…
Anthropic launched Claude Science on June 30, an AI research platform integrating 60+ tools for drug discovery focused on…
